{"filing":{"accession_number":"0001193125-26-426811","cik":"0001750149","ticker":"IKT","company_name":"Inhibikase Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-19","primary_document":"d190975d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/d190975d8k.htm"},"events":[{"id":36468,"run_id":33625,"accession_number":"0001193125-26-426811","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Scott M. Wasserman, MD was appointed as a Class III director and member of the Compensation Committee effective October 19, 2026, bringing significant clinical development expertise to support the Company's Phase 3 IMPROVE-PAH study. The appointment includes equity compensation of 310,000 stock options. Dennis Berman's concurrent resignation is noted but secondary to the forward-looking appointment.","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40892,"accession_number":"0001193125-26-426811","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Scott Wasserman as a Class III director and member of the Compensation Committee, effective October 19, 2026. While the section also mentions Dennis Berman's resignation, the substantive focus and forward-looking implications center on Dr. Wasserman's appointment and his significant clinical development expertise relevant to the Company's Phase 3 IMPROVE-PAH study. The appointment includes equity compensation (310,000 stock options) and committee service, making it a material governance event affecting board composition and leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:58:40.347407+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40893,"accession_number":"0001193125-26-426811","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Scott M. Wasserman, MD to Inhibikase's Board of Directors effective October 19, 2026. While the press release also mentions the concurrent resignation of Dennis Berman, the principal disclosed action and focus of the announcement is Dr. Wasserman's appointment, emphasizing his extensive clinical development expertise and anticipated contributions to the company's Phase 3 IMPROVE-PAH study. This is a material governance event affecting board composition at a clinical-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:58:40.347407+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40892,"accession_number":"0001193125-26-426811","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Scott Wasserman as a Class III director and member of the Compensation Committee, effective October 19, 2026. While the section also mentions Dennis Berman's resignation, the substantive focus and forward-looking implications center on Dr. Wasserman's appointment and his significant clinical development expertise relevant to the Company's Phase 3 IMPROVE-PAH study. The appointment includes equity compensation (310,000 stock options) and committee service, making it a material governance event affecting board composition and leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:58:40.347407+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-10-20"},{"id":40893,"accession_number":"0001193125-26-426811","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Scott M. Wasserman, MD to Inhibikase's Board of Directors effective October 19, 2026. While the press release also mentions the concurrent resignation of Dennis Berman, the principal disclosed action and focus of the announcement is Dr. Wasserman's appointment, emphasizing his extensive clinical development expertise and anticipated contributions to the company's Phase 3 IMPROVE-PAH study. This is a material governance event affecting board composition at a clinical-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:58:40.347407+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-10-20"}]}